Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:PLX)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

PR Newswire December 9, 2024

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Business Wire September 17, 2024

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

PR Newswire June 13, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

ACCESS Newswire June 11, 2024

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

PR Newswire March 14, 2024

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PR Newswire September 12, 2023

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire September 6, 2023

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

PR Newswire August 1, 2023

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

PR Newswire June 8, 2023
View More News ››

Opinion & Analysis (NYSEAM:PLX)

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Streetwise Reports October 18, 2019

Price Target on Biotech Is a 700% Potential Increase

Streetwise Reports March 21, 2018
View More Opinion ››

Bullboard Posts (NYSEAM:PLX)

Protalix BioTherapeutics to Participate in the 2025 BIO CEO

Breaking News: $PLX Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor ConferenceProtalix BioTherapeutics to...
whytestocks - February 4, 2025

ProCell Opportunity: Protalix BioTherapeutics (NYSE American

http://beyondspx.com/2024/08/01/procell-opportunity-protalix-biotherapeutics-nyse-american-plx/
MikeTester - August 2, 2024

Interesting times

Interesting times ahead. 
ExplodeTheBank - June 15, 2023

RE:RE:Charlie

Great call on the .65 break, down to .55...we reached .57. I would guess by looking at chart .50 cents should be line in the sand.
Paparico1 - March 15, 2018

?????

Protalix: It's Time To Sell Mar. 14, 2018 10:58 AM ET | 2 comments |  About: ...
skyhigh123 - March 14, 2018

RE:Charlie

I haven't been on PLX BB for sometime but been rereading old stuff. Chart looks like it's coming to a cross road again and weekly...
Paparico1 - February 4, 2018
View more Bullboard ››

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving ...
View More »